A detailed history of Dimensional Fund Advisors LP transactions in Milestone Pharmaceuticals Inc. stock. As of the latest transaction made, Dimensional Fund Advisors LP holds 39,450 shares of MIST stock, worth $71,010. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,450
Previous 39,450 -0.0%
Holding current value
$71,010
Previous $52,000 13.46%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$1.4 - $2.2 $47,955 - $75,358
-34,254 Reduced 46.48%
39,450 $70,000
Q4 2023

Feb 07, 2024

SELL
$1.67 - $3.39 $21,935 - $44,527
-13,135 Reduced 15.13%
73,704 $123,000
Q3 2023

Nov 09, 2023

SELL
$2.68 - $3.69 $249,636 - $343,716
-93,148 Reduced 51.75%
86,839 $269,000
Q2 2023

Aug 09, 2023

SELL
$2.85 - $4.4 $9,282 - $14,330
-3,257 Reduced 1.78%
179,987 $512,000
Q1 2023

May 12, 2023

SELL
$3.14 - $4.2 $10,930 - $14,620
-3,481 Reduced 1.86%
183,244 $721,000
Q4 2022

Feb 09, 2023

BUY
$3.53 - $9.5 $400,482 - $1.08 Million
113,451 Added 154.83%
186,725 $739,000
Q3 2022

Nov 10, 2022

SELL
$5.86 - $9.43 $12,141 - $19,538
-2,072 Reduced 2.75%
73,274 $673,000
Q2 2022

Aug 12, 2022

BUY
$5.13 - $7.37 $69,783 - $100,254
13,603 Added 22.03%
75,346 $448,000
Q1 2022

May 13, 2022

BUY
$4.1 - $8.24 $37,576 - $75,519
9,165 Added 17.43%
61,743 $397,000
Q4 2021

Feb 09, 2022

BUY
$5.47 - $7.13 $38,623 - $50,344
7,061 Added 15.51%
52,578 $345,000
Q3 2021

Nov 12, 2021

SELL
$5.28 - $6.29 $8,886 - $10,586
-1,683 Reduced 3.57%
45,517 $260,000
Q2 2021

Aug 12, 2021

BUY
$5.22 - $6.11 $46,374 - $54,281
8,884 Added 23.19%
47,200 $260,000
Q1 2021

May 14, 2021

BUY
$5.79 - $8.85 $92,414 - $141,254
15,961 Added 71.4%
38,316 $222,000
Q4 2020

Feb 25, 2021

BUY
$5.57 - $7.66 $124,517 - $171,239
22,355 New
22,355 $150,000

Others Institutions Holding MIST

About Milestone Pharmaceuticals Inc.


  • Ticker MIST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,010,900
  • Market Cap $54M
  • Description
  • Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...
More about MIST
Track This Portfolio

Track Dimensional Fund Advisors LP Portfolio

Follow Dimensional Fund Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Dimensional Fund Advisors LP with notifications on news.